Amy J Schwinghammer1, Alex N Isaacs2,3, Rodney W Benner4, Heather Freeman5, Jacob A O'Sullivan6, Sarah A Nisly7. 1. 1 University of California Davis Medical Center, Sacramento, CA, USA. 2. 2 Purdue University College of Pharmacy, Indianapolis, IN, USA. 3. 3 Eskenazi Health, Indianapolis, IN, USA. 4. 4 Shelbourne Knee Center, Indianapolis, IN, USA. 5. 5 University of Indianapolis, Indianapolis, IN, USA. 6. 6 Indiana University School of Medicine, Indianapolis, IN, USA. 7. 7 Wingate University School of Pharmacy, Wingate, NC, USA.
Abstract
BACKGROUND: Previous clinical trials have demonstrated benefit with the addition of continuous infusion (CI) ketorolac to a multimodal pain regimen in surgical patients. Data following major orthopedic surgery are minimal and conflicting. OBJECTIVES: To evaluate CI ketorolac use following unilateral total knee arthroplasty (TKA) through assessment of patient-reported pain scores, opioid consumption, and safety outcomes. METHODS: This was a retrospective, open-label cohort study that included patients undergoing unilateral TKA at a single-center teaching hospital. Participants were categorized into 2 study groups based on postoperative management: CI ketorolac or opioid protocol (OP). The first group received a ketorolac 30-mg bolus followed by CI 3.6 mg/h plus as-needed (PRN) opioids. The OP group received PRN narcotics in a tiered protocol. The primary end point was comparison of median pain scores. Secondary end points included opioid consumption (morphine equivalent units [MEUs]) in the first 48 hours postoperatively, length of stay, and adverse effects. RESULTS: Of 447 patients screened, 191 were analyzed (CI ketorolac, n = 116; OP, n = 75). Median pain scores were significantly lower in the CI ketorolac group at 48 hours postoperatively (3 [2-4] vs 3.5 [2.5-5], P = 0.033). Cumulative MEUs at 48 hours were significantly lower in the CI ketorolac group (33.9 ± 38.5 mg vs 301.6 ± 36.6 mg, P < 0.001). Patients in the CI ketorolac group experienced less respiratory depression (5.2% vs 25.3%, P < 0.001) and less naloxone administration (0% vs 8%, P = 0.002) compared with the OP group. Other adverse effects were similar among groups. CONCLUSIONS: Postoperative CI ketorolac improved pain control while reducing opioid consumption and adverse effects.
BACKGROUND: Previous clinical trials have demonstrated benefit with the addition of continuous infusion (CI) ketorolac to a multimodal pain regimen in surgical patients. Data following major orthopedic surgery are minimal and conflicting. OBJECTIVES: To evaluate CI ketorolac use following unilateral total knee arthroplasty (TKA) through assessment of patient-reported pain scores, opioid consumption, and safety outcomes. METHODS: This was a retrospective, open-label cohort study that included patients undergoing unilateral TKA at a single-center teaching hospital. Participants were categorized into 2 study groups based on postoperative management: CI ketorolac or opioid protocol (OP). The first group received a ketorolac 30-mg bolus followed by CI 3.6 mg/h plus as-needed (PRN) opioids. The OP group received PRN narcotics in a tiered protocol. The primary end point was comparison of median pain scores. Secondary end points included opioid consumption (morphine equivalent units [MEUs]) in the first 48 hours postoperatively, length of stay, and adverse effects. RESULTS: Of 447 patients screened, 191 were analyzed (CI ketorolac, n = 116; OP, n = 75). Median pain scores were significantly lower in the CI ketorolac group at 48 hours postoperatively (3 [2-4] vs 3.5 [2.5-5], P = 0.033). Cumulative MEUs at 48 hours were significantly lower in the CI ketorolac group (33.9 ± 38.5 mg vs 301.6 ± 36.6 mg, P < 0.001). Patients in the CI ketorolac group experienced less respiratory depression (5.2% vs 25.3%, P < 0.001) and less naloxone administration (0% vs 8%, P = 0.002) compared with the OP group. Other adverse effects were similar among groups. CONCLUSIONS: Postoperative CI ketorolac improved pain control while reducing opioid consumption and adverse effects.
Entities:
Keywords:
analgesia; bone/joint disorders; dosing; drug administration; narcotics; nonsteroidal anti-inflammatory drugs; orthopedics; pain management; surgery
Authors: Max L Willinger; Jamie Heimroth; Nipun Sodhi; Luke J Garbarino; Peter A Gold; Vijay Rasquinha; Jonathan R Danoff; Sreevathsa Boraiah Journal: Curr Pain Headache Rep Date: 2021-04-17
Authors: Patricia C Dykes; Mica Curtin-Bowen; Troy Li; Avery Pullman; Alexandra Businger; Stuart Lipsitz; Ania Syrowatka; Michael Sainlaire; Tien Thai; David W Bates Journal: AMIA Annu Symp Proc Date: 2022-02-21
Authors: Kevin Berardino; Austin H Carroll; Robert Ricotti; Daniel Popovsky; Matthew D Civilette; Ivan Urits; Omar Viswanath; William F Sherman; Alan D Kaye Journal: Orthop Rev (Pavia) Date: 2022-08-30
Authors: Kathleen M Antony; Jacquelyn H Adams; Laura Jacques; Scott Hetzel; Richard J Chappell; Sarah E Gnadt; Amye J Tevaarwerk Journal: Am J Obstet Gynecol MFM Date: 2020-11-26
Authors: Nicole E George; Cheryle Gurk-Turner; Nequesha S Mohamed; Wayne A Wilkie; Ethan A Remily; Iciar M Dávila Castrodad; Elana Roadcloud; Ronald Delanois Journal: Cureus Date: 2020-03-18